Skip to main content
Advanced Search
  • Jun 12, 2020
    Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020

    KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...

  • Jun 8, 2020
    Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation

    HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...

  • Jun 8, 2020
    • Builds on CSL Behring’s promise and commitment to the transplant community

    KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...

  • Jun 2, 2020
    Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)

    SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...

  • May 27, 2020
    Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.

    WALTHAM, Mass. and KING OF PRUSSIA, Penn. 27 May 2020 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited...

Show 5102550100 per page
Get our latest news releases in your inbox
* Required Fields